China Resources Double-Crane announced that its Lomustine Capsules, filed as the domestic agent, have received a drug registration certificate from the National Medical Products Administration. The specification is 40 mg, and the registration classification is chemical drug category 5.1. It is indicated for children and adult patients with primary malignant brain tumors, and enjoys a six-year data protection period. The product was introduced by the company from Latina Pharma S.P.A in early 2024, with a marketing authorization application submitted in January 2024. Cumulative research and development investment is approximately 2.23 million yuan.
China Resources Double-Crane Pharmaceutical Co LtdReceived drug registration certificate for Lomustine Capsules, a new product approval.
Beijing Winsunny Pharmaceutical CO.LTD